Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC

Test Being Developed to Diagnose Mild Cognitive Impairment

By Labmedica International staff writers
Posted on 18 Feb 2013
Autoantibody biomarkers in the blood can potentially be used to diagnose early stages of Alzheimer's and Parkinson's diseases.

A grant of USD 799,800 from the Osteopathic Heritage Foundation at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (Stratford, NJ, USA) will help expand earlier research conducted by Robert Nagele, PhD, director of the Biomarker Discovery Center (at the University). Dr. Nagele's published research includes recent findings that identify specific autoantibody biomarkers in the blood for early diagnosis of Alzheimer's and Parkinson's diseases.

The funded project will pursue three specific goals: to identify a small number of autoantibody biomarkers that can accurately (90% or higher) diagnose MCI cases caused by early stage Alzheimer's disease; to verify the accuracy rate with a larger scale study; and to construct and test a diagnostic kit that is maximally accurate for the broadest possible MCI patient population. If successful, the study will then apply for final US Food and Drug Administration (FDA; Silver Spring, MD, USA) approval of the test.

"Using our novel biomarker discovery strategy, we have shown that it is possible to use a single drop of blood to diagnose Alzheimer's and Parkinson's with greater than 95% accuracy," said Dr Nagele. "This same approach should also allow us to identify a small number of biomarkers that can also accurately diagnose MCI caused by early-stage Alzheimer's disease."

Current approaches to MCI diagnosis rely on physical, neurological, and psychiatric examinations, laboratory tests, and a thorough review of the patient's medications and medical history. Recently, great attention has been given to using neuroimaging technologies to detect structural changes in the brain before symptoms appear. However, these approaches require expensive equipment and technology and can require hospital visits, the injection of radioactive compounds, and the availability of radiologists with advanced training in these techniques.

While current treatments for Alzheimer's cannot stop the progression of the disease, several medications are capable of significantly enhancing brain performance and alleviating symptoms. A number of promising drugs are also currently under development and in clinical trials for the treatment of early Alzheimer's disease. An easy-to-administer blood test for MCI would give pharmaceutical companies a way to identify patients for clinical trials who are at a very early stage of their disease and give researchers a nearly immediate way to monitor the effectiveness of medications under examination.

Related Links:

University of Medicine and Dentistry of New Jersey
US Food and Drug Administration



KARL HECHT GMBH & CO KG
MEDLAB Asia
CELLAVISION AB

Channels

Microbiology

view channel
Image: The Xpert MTB/RIF cartridge-based, fully automated molecular diagnostic test for tuberculosis (Photo courtesy of Cepheid).

Test Helps Physicians Remove Suspected TB Patients from Isolation

Tuberculosis (TB) is caused by the Mycobacterium tuberculosis complex (MTB-complex) and usually attacks the lungs and many people carry the MTB-complex bacteria without ever developing active disease.... Read more

Lab Tech.

view channel
Image:  The Flame – a miniature spectrometer for medical diagnostics, biotechnology, and life sciences, that brings flexible optical sensing power to laboratory and point-of-care instrument integration (Photo courtesy of Ocean Optics).

Next Generation Miniature Spectrometer Brings Flexibility to Diagnostics and Biotechnology

The mini spectrometer combines decades of pioneering miniature spectrometer design expertise with leading techniques, adding flexible optical sensing power to laboratory and point-of-care instrument integration.... Read more

Industry News

view channel
Image: Under a new partnership for liquid handling measurement automation, Artel will provide STRATEC’s innovative “Tholos” technology, which measures liquid and solid contents of 96- and 384-well microplates, under the name Artel “SDS” - Sample Detection System (Photo courtesy of Artel).

Artel Expands Portfolio with STRATEC Partnership for Automation Technology

Artel (Westbrook, Maine, USA), a leader in laboratory liquid handling measurement systems, and STRATEC Biomedical AG (Birkenfeld, Germany), a leader in automated systems for clinical diagnostics and biotechnology,... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
08 Mar 2015 - 12 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.